UK Authorizes Alzheimer's Drug Leqembi Amid Controversy Over its Value

The UK's drug regulator authorised Leqembi, the first medicine to slow Alzheimer's progression. However, an independent agency deemed it not cost-effective for taxpayers, likely preventing government-funded availability. Experts highlight the minimal benefits and lack of long-term data, while others warn of increasing inequities in healthcare access.

The UK's drug regulator has approved Leqembi, the first medicine to show potential in slowing the progression of Alzheimer's disease. However, it is unlikely to be funded by the government, following draft guidance from an independent agency deeming it not cost-effective for taxpayers.

The high costs associated with Leqembi, including the need for bi-weekly hospital visits and close monitoring, have raised concerns. Experts also note the absence of data on its long-term effectiveness. Dr. Samantha Robers of NICE stated the drug's benefits don't justify its significant cost.

The guidance is open for public consultation before final advice is issued. While private prescriptions remain available, some fear this may deepen healthcare inequities. The US FDA approved Leqembi last year, but the European Medicines Agency has not recommended its use.

(With inputs from agencies.)